

Goserelin Acetate

Catalog No.	CRG511A	Quantity:	5 mg
	CRG511B		25 mg
	CRG511C		100 mg

Description: Goserelin has actions similar to those of naturally occurring LHRH. LHRH released from the hypothalamus stimulates receptors on the pituitary gland, which then releases the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Goserelin and other LHRH agonists provide a medical castration that deprives hormonally-dependent tumors of testosterone or estrogen. Normally, LHRH is released in a pulsatile manner to maintain levels of gonadotropins. Goserelin, in contrast, is continuously administered, which leads to downregulation of the LHRH receptor on the pituitary gland and decreased production of FSH and LH. During short-term or intermittent treatment, goserelin has the same stimulatory action as LHRH. This stimulation produces a surge of FSH and LH, which can cause a flare reaction in patients with prostate or breast carcinoma.

Source: Synthetic

Formulation: Sterile Filtered White lyophilized (freeze-dried) powder. Lyophilized from a concentrated (1 mg/ml) solution in water containing no additives.

Purity: Greater than 98.0% as determined by: Analysis by RP-HPLC, anion-exchange FPLC, and analysis by reducing and non-reducing SDS-PAGE Silver Stained gel.

Amino Acid Sequence: Glu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-AzGly-NH₂

Reconstitution: It is recommended to reconstitute the lyophilized Goserelin in sterile, distilled H₂O not less than 100 µg/ml, which can then be further diluted to other aqueous solutions.

Storage & Stability: Lyophilized Goserelin although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Goserelin should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Avoid freeze-thaw cycles.

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.